Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bacterial Infections and Mycoses
  Free Subscription

Articles published in
Lancet
    October 2025
  1. BURDET C, Saidani N, Dupieux C, Lemaignen A, et al
    Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.
    Lancet. 2025 Oct 17:S0140-6736(25)01624-1. doi: 10.1016/S0140-6736(25)01624.
    >> Share

  2. HENDRICK J, Raqib R, Noor Z, Faruque ASG, et al
    Shigellosis.
    Lancet. 2025;406:1508-1519.
    >> Share

    September 2025
  3. KUEHN R, Rahden P, Hussain HS, Karkey A, et al
    Enteric (typhoid and paratyphoid) fever.
    Lancet. 2025;406:1283-1294.
    >> Share

    August 2025
  4. DROBNIEWSKI F, Kon OM, Gonzalo X, Ashmi M, et al
    Why are we failing to rapidly diagnose tuberculosis in the UK?
    Lancet. 2025;406:908-909.
    >> Share

    July 2025
  5. ABUZERR S, Hamdan H, Charafeddine J
    Paediatric meningitis outbreak in Gaza amid health system collapse.
    Lancet. 2025 Jul 31:S0140-6736(25)01520-X. doi: 10.1016/S0140-6736(25)01520.
    >> Share

  6. MACIEL EL, Pablos-Mendez A, Abubakar I
    Undoing progress through sudden tuberculosis funding cuts.
    Lancet. 2025 Jul 3:S0140-6736(25)01328-5. doi: 10.1016/S0140-6736(25)01328.
    >> Share

  7. HALLETT TB, Menzies NA, Resch S, Pretorius C, et al
    The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study.
    Lancet. 2025 Jul 3:S0140-6736(25)00831-1. doi: 10.1016/S0140-6736(25)00831.
    >> Share

    June 2025
  8. HIRANI K, Rwebembera J, Webb R, Beaton A, et al
    Acute rheumatic fever.
    Lancet. 2025;405:2164-2178.
    >> Share

  9. AL ZAMEL AM, Saeed AA, Elmubarak M, Alsarraj MA, et al
    Sudan's tuberculosis response needs global support amid conflict.
    Lancet. 2025 Jun 2:S0140-6736(25)01119-5. doi: 10.1016/S0140-6736(25)01119.
    >> Share

    May 2025
  10. HABTAMU E, Harding-Esch EM, Greenland K, Wamyil-Mshelia T, et al
    Trachoma.
    Lancet. 2025;405:1865-1878.
    >> Share

  11. SUNDAR R, Nakayama I, Markar SR, Shitara K, et al
    Gastric cancer.
    Lancet. 2025 May 1:S0140-6736(25)00052-2. doi: 10.1016/S0140-6736(25)00052.
    >> Share

    April 2025
  12. ROSS JDC, Wilson J, Workowski KA, Taylor SN, et al
    Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
    Lancet. 2025 Apr 11:S0140-6736(25)00628-2. doi: 10.1016/S0140-6736(25)00628.
    >> Share

  13. KLUGE HHP
    Tuberculosis: a threat to health security in the European region and the collective actions needed.
    Lancet. 2025 Apr 7:S0140-6736(25)00677-4. doi: 10.1016/S0140-6736(25)00677.
    >> Share

    March 2025
  14. DHEDA K, Perumal T, Fox GJ
    Asymptomatic tuberculosis: undetected and underestimated, but not unimportant.
    Lancet. 2025 Mar 21:S0140-6736(25)00555-0. doi: 10.1016/S0140-6736(25)00555.
    >> Share

  15. JERENE D, van Kalmthout K, Levy J, Alacapa J, et al
    Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.
    Lancet. 2025 Mar 11:S0140-6736(24)02847-2. doi: 10.1016/S0140-6736(24)02847.
    >> Share

  16. MARX FM, Civan A
    Rethinking the benefits of digital adherence technologies for tuberculosis treatment.
    Lancet. 2025 Mar 11:S0140-6736(25)00199-0. doi: 10.1016/S0140-6736(25)00199.
    >> Share

  17. TROTTER C, Diallo K
    Another step towards defeating meningitis.
    Lancet. 2025 Mar 11:S0140-6736(25)00196-5. doi: 10.1016/S0140-6736(25)00196.
    >> Share

  18. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
    Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
    Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
    >> Share

  19. TRAJMAN A, Campbell JR, Kunor T, Ruslami R, et al
    Tuberculosis.
    Lancet. 2025;405:850-866.
    >> Share

    February 2025
  20. ZUMLA A, Sahu S, Yeboah-Manu D, Goletti D, et al
    Breaking dependency: strengthening the global tuberculosis response in the face of USAID cuts.
    Lancet. 2025 Feb 26:S0140-6736(25)00335-6. doi: 10.1016/S0140-6736(25)00335.
    >> Share

  21. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    >> Share

    January 2025
  22. MACESIC N, Uhlemann AC, Peleg AY
    Multidrug-resistant Gram-negative bacterial infections.
    Lancet. 2025;405:257-272.
    >> Share

    October 2024
  23. BHARGAVA A, Bhargava M, Velayutham B, Benedetti A, et al
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial - Authors' reply.
    Lancet. 2024;404:1524.
    >> Share

  24. ZHANG K, Xu Y, Hu Y, Chen X, et al
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1523-1524.
    >> Share

  25. BUSANG J, Khan P
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1522-1523.
    >> Share

  26. RICKMAN HM, Yates TA
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1522.
    >> Share

  27. KAUR JABINDA M
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1521-1522.
    >> Share

  28. QADRI F, Khanam F, Zhang Y, Biswas PK, et al
    5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Lancet. 2024;404:1419-1429.
    >> Share

  29. BHATTARAI MD
    Utilising available isoniazid-resistance tests in new patients.
    Lancet. 2024;404:1403.
    >> Share

  30. AL-MAMUN F, Mamun MA, Roy N
    Long-term efficacy and public health implications of the Vi-tetanus toxoid conjugate vaccine in Bangladeshi children.
    Lancet. 2024;404:1378-1379.
    >> Share

    September 2024
  31. KHAN M
    "The final warning sign": XDR typhoid.
    Lancet. 2024;404:1182-1183.
    >> Share

  32. VAN RHIJN N, Arikan-Akdagli S, Beardsley J, Bongomin F, et al
    Beyond bacteria: the growing threat of antifungal resistance.
    Lancet. 2024;404:1017-1018.
    >> Share


  33. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.
    Lancet. 2024 Sep 13:S0140-6736(24)01867-1. doi: 10.1016/S0140-6736(24)01867.
    >> Share

  34. HIRATE T, Kanda K, Ohshima Y, Shinoda K, et al
    Congenital syphilis in a 2-month-old infant during Japanese outbreak.
    Lancet. 2024;404:971.
    >> Share

    August 2024
  35. NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al
    Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
    Lancet. 2024;404:748.
    >> Share

  36. OBARO S
    Efficacy of typhoid conjugate vaccine in Malawian children.
    Lancet. 2024;404:747-748.
    >> Share

    July 2024
  37. LI M, Kim JB, Sastry BKS, Chen M, et al
    Infective endocarditis.
    Lancet. 2024;404:377-392.
    >> Share

    June 2024
  38. HYDE L
    Mobile screening for Ukraine's wartime tuberculosis epidemic.
    Lancet. 2024;403:2771.
    >> Share

  39. MCCANN N, Vicentine MP, Pollard AJ
    Towards paratyphoid control: the vital role of the challenge model.
    Lancet. 2024;403:2780-2781.
    >> Share

  40. CRENNER C
    Ulcers, stress, and the discovery of Helicobacter pylori.
    Lancet. 2024;403:2586-2587.
    >> Share

  41. WHITE NJ
    Death from diphtheria.
    Lancet. 2024;403:2590-2591.
    >> Share

  42. LIOU JM, Malfertheiner P, Smith SI, El-Omar EM, et al
    40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention.
    Lancet. 2024;403:2570-2572.
    >> Share

  43. ALMADI MA, Lu Y, Alali AA, Barkun AN, et al
    Peptic ulcer disease.
    Lancet. 2024 Jun 14:S0140-6736(24)00155-7. doi: 10.1016/S0140-6736(24)00155.
    >> Share

  44. MARIONI G, Franz L, Incognito A, Bitonti S, et al
    Bilateral simultaneous cochlear implant in an adult with anacusis due to bacterial meningitis.
    Lancet. 2024;403:2533.
    >> Share

  45. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    >> Share

  46. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    >> Share

    May 2024
  47. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    >> Share

  48. LEWNARD JA, Charani E, Gleason A, Hsu LY, et al
    Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
    Lancet. 2024 May 20:S0140-6736(24)00862-6. doi: 10.1016/S0140-6736(24)00862.
    >> Share

  49. OKEKE IN, de Kraker MEA, Van Boeckel TP, Kumar CK, et al
    The scope of the antimicrobial resistance challenge.
    Lancet. 2024 May 20:S0140-6736(24)00876-6. doi: 10.1016/S0140-6736(24)00876.
    >> Share

  50. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    >> Share

  51. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    >> Share

    March 2024
  52. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    >> Share

  53. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    >> Share

  54. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    >> Share

  55. BHARGAVA A, Bhargava M, Pai M
    Tuberculosis: a biosocial problem that requires biosocial solutions.
    Lancet. 2024 Mar 20:S0140-6736(24)00489-6. doi: 10.1016/S0140-6736(24)00489.
    >> Share

  56. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    >> Share

  57. SUBBARAMAN R, Fielding K
    Putting technology to the test in tuberculosis care.
    Lancet. 2024;403:878-879.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016